Glial Fibrillary Acidic Protein (GFAP) Autoimmunity in the Setting of Seropositive Rheumatoid Arthritis Treated with Etanercept

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Introduction:Glial fibrillary acidic protein (GFAP) immunoglobulin G is a recently discovered biomarker of an autoimmune central nervous system disorder characterized by a steroid-responsive meningoencephalomyelitis.Case Report:A 63-year-old man with rheumatoid arthritis on etanercept presented with steroid-responsive subacute encephalopathy and foot drop. Brain and sural nerve biopsies demonstrated a T-cell perivascular infiltrate. Cerebrospinal fluid studies 18 months into the course of the illness demonstrated a GFAP antibody on mouse tissue immunofluorescence confirmed by cell-based assay. The patient was treated with steroids and cyclophosphamide leading to resolution of his symptoms.Conclusion:This case expands on the previously reported cases of GFAP immunoglobulin G autoimmunity by describing an associated inflammatory large fiber peripheral neuropathy.

Original languageEnglish (US)
Pages (from-to)152-154
Number of pages3
JournalNeurologist
Volume24
Issue number5
DOIs
StatePublished - Sep 1 2019

Keywords

  • GFAP
  • TNF-inhibitor
  • encephalopathy
  • neuroimmunology
  • neuropathy

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Glial Fibrillary Acidic Protein (GFAP) Autoimmunity in the Setting of Seropositive Rheumatoid Arthritis Treated with Etanercept'. Together they form a unique fingerprint.

Cite this